Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
31.94
-0.56 (-1.72%)
At close: Jul 6, 2026, 4:00 PM EDT
31.96
+0.02 (0.06%)
After-hours: Jul 6, 2026, 5:05 PM EDT
Immunocore Holdings Employees
Immunocore Holdings had 524 employees as of December 31, 2025. The number of employees increased by 31 or 6.29% compared to the previous year.
Employees
524
Change (1Y)
31
Growth (1Y)
6.29%
Revenue / Employee
$787,809
Profits / Employee
-$52,607
Market Cap
1.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 524 | 31 | 6.29% |
| Dec 31, 2024 | 493 | -4 | -0.80% |
| Dec 31, 2023 | 497 | 89 | 21.81% |
| Dec 31, 2022 | 408 | 84 | 25.93% |
| Dec 31, 2021 | 324 | 33 | 11.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Ascentage Pharma Group International | 767 |
| Novavax | 749 |
| Vir Biotechnology | 367 |
| Zenas BioPharma | 167 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| MapLight Therapeutics | 133 |
IMCR News
- 5 weeks ago - Immunocore presents updated results from Phase 1/2 trial of brenetafusp - TheFly
- 5 weeks ago - Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma - GlobeNewsWire
- 7 weeks ago - Immunocore Holdings Slides: Corporate presentation - Filings
- 2 months ago - Immunocore reports first quarter financial results and provides a business update - GlobeNewsWire
- 2 months ago - Immunocore Holdings Quarterly report: Q1 2026 - Filings
- 2 months ago - Immunocore Holdings Earnings release: Q1 2026 - Filings
- 2 months ago - Immunocore announces five-year overall survival data for Kimmtrak - TheFly
- 2 months ago - KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma - GlobeNewsWire